Selecta in pact to shift ImmTOR for SEL-212 rights and clinical ops to Sobi

Selecta Biosciences announced that it has entered into an agreement to transition the manufacturing and development rights and remaining clinical operations of ImmTOR for SEL-212 to its development and commercialization partner, Swedish Orphan Biovitrum or Sobi. As of November 6 Sobi will assume responsibility for the manufacturing and commercial supply of ImmTOR for SEL-212. SEL-212, a combination of Selecta’s ImmTOR immune tolerance platform and a therapeutic uricase enzyme pegadricase is in development for the treatment of chronic refractory gout. A Biologics License Application BLA submission for SEL-212 remains on track for the first half of 2024…”Leveraging ImmTOR, the only immune tolerance platform with positive Phase 3 data, we firmly believe that SEL-212 has strong potential to address this significant unmet need and exceed $700M in peak sales in the U.S.” Sobi licensed SEL-212 from Selecta in June 2020 and is responsible for development, regulatory and commercial activities in all markets outside of China. Selecta was originally responsible for ImmTOR manufacturing. Selecta is eligible to receive up to $615M in remaining regulatory and commercial milestone payments and tiered double-digit royalties on net sales of SEL-212.